Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of cells in the laboratory from patients with cancer may help identify biomarkers related to cancer. It may also help doctors learn how patients respond to treatment.
PURPOSE: This laboratory study is analyzing samples of cells from patients with chronic lymphocytic leukemia who were treated on clinical trial ECOG-2997.
Genetic: cytogenetic analysis
Other: flow cytometry
Other: fluorescence activated cell sorting
Other: immunoenzyme technique
Other: laboratory biomarker analysis
|Official Title:||Proposed Study of CLL Samples|
- Correlation of biomarker analysis with complete response [ Designated as safety issue: No ]
- Correlation of biomarker analysis with progression-free survival [ Designated as safety issue: No ]
- Correlation of biomarker analysis with overall survival [ Designated as safety issue: No ]
|Study Start Date:||August 2008|
|Estimated Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
- To analyze the expression of a variety of informative molecules using a unique high-resolution flow cytometric immunophenotyping technology in samples from patients with chronic lymphocytic leukemia enrolled in clinical trial ECOG-2997.
OUTLINE: Cell samples are analyzed for the following prognostic biomarkers: ZAP-70, phospho-Syk, phospho-GSK-3β, phospho-Akt, phospho-ZAP-70, cyclin D1, cyclin D2, p21cip1, phospho-ReIA, IkappaBα, Bax, Mcl-1, PTEN, phospho-Erk1/2, and phospho-MEK1/2. Biomarker signals are amplified using enzymatic amplification staining to obtain high resolution detection of cell-surface markers on leukemic cells. Biomarker expression levels are measured using fluorescence activated cell sorting analysis. Relationships between clinical outcomes, standard flow cytometric analysis, cytogenetic studies, and high resolution immunophenotyping will also be assessed.
|Study Chair:||David Kaplan, MD, PhD||University Hospitals Seidman Cancer Center|